See What HealthDay Can Do For You
Contact Us

Molecular Tumor Burden Predicts Colon Cancer Outcome

Occult metastases in histopathologically cancer-free nodes independently predict prognosis

THURSDAY, March 3 (HealthDay News) -- In patients with node-negative colorectal cancer, the occult molecular tumor burden in the lymph nodes is an independent predictor of the time to recurrence and disease-free survival, according to a study published online Feb. 9 in Clinical Cancer Research.

Terry Hyslop, Ph.D., of Thomas Jefferson University in Philadelphia, and colleagues investigated the link between occult nodal metastases, measured via the molecular tumor marker guanylyl cyclase C (GUCY2C), and prognosis in node-negative colorectal cancer patients. Lymph nodes of 291 node-negative patients were examined by histopathology, and occult tumor burden was measured by quantifying GUCY2C. Patients were followed for a median time period of 24 months, with time to recurrence as the primary end point and disease-free survival as the secondary end point.

The researchers found that the occult tumor burden independently predicted prognosis. With increasing molecular tumor burden, the time to recurrence and disease-free survival decreased. Of the 176 patients with a low tumor burden, all but four remained disease-free. Of the 90 patients with an intermediate tumor burden, 30 had recurrent cancer; whereas, among the 25 patients with a high tumor burden, 17 developed recurrent cancer.

"We demonstrate for the first time that occult tumor burden assessed across the regional lymph node network is a powerful independent prognostic marker of time to recurrence and disease-free survival in pN0 [node-negative colorectal cancer] patients. This approach can improve prognostic risk stratification and chemotherapeutic allocation in pN0 patients," the authors write.

One of the authors disclosed a financial relationship, and another a professional relationship (uncompensated), with Targeted Diagnostics & Therapeutics Inc., which partially funded this study.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.